New drug combo tested for Tough-to-Treat esophageal cancer
NCT ID NCT06753747
Summary
This study is testing a combination of two oral drugs, afatinib and palbociclib, for people with advanced esophageal cancer that has returned or spread after prior treatment. The first part aims to find a safe dose, and the second part will see if the combination can shrink tumors. It is for up to 45 adults whose cancer has specific genetic features and who are otherwise healthy enough to participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.